REPLIGEN CORP
10-Q, EX-27.1, 2000-08-11
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: REPLIGEN CORP, 10-Q, EX-10.1, 2000-08-11
Next: CLARIDGE HOTEL & CASINO CORP, 10-Q, 2000-08-11



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE FINANCIAL
STATEMENTS FOR REPLIGEN CORPORATION AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          26,015
<SECURITIES>                                     7,822
<RECEIVABLES>                                      436
<ALLOWANCES>                                      (25)
<INVENTORY>                                        543
<CURRENT-ASSETS>                                35,029
<PP&E>                                           1,771
<DEPRECIATION>                                 (1,275)
<TOTAL-ASSETS>                                  35,607
<CURRENT-LIABILITIES>                              786
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           266
<OTHER-SE>                                      34,555
<TOTAL-LIABILITY-AND-EQUITY>                    35,607
<SALES>                                            556
<TOTAL-REVENUES>                                 1,173
<CGS>                                              330
<TOTAL-COSTS>                                    2,144
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (971)
<EPS-BASIC>                                      (.04)
<EPS-DILUTED>                                    (.04)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission